Hims & Hers Health (NYSE:HIMS) Issues Earnings Results

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings results on Monday. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.04, FiscalAI reports. The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%.

Hims & Hers Health Trading Down 1.0%

Shares of Hims & Hers Health stock traded down $0.16 during trading hours on Monday, reaching $15.47. The stock had a trading volume of 34,039,939 shares, compared to its average volume of 26,693,072. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of 28.64, a P/E/G ratio of 2.92 and a beta of 2.43. Hims & Hers Health has a 1 year low of $15.15 and a 1 year high of $70.43. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a 50 day simple moving average of $28.63 and a two-hundred day simple moving average of $40.27.

Hims & Hers Health declared that its board has approved a share repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Barclays initiated coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 target price on the stock. Citigroup lowered their price objective on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a research report on Monday, February 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. TD Cowen decreased their price target on Hims & Hers Health from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Monday, February 9th. Finally, UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $39.32.

Insider Activity

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the transaction, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider directly owned 6,175 shares in the company, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 82,963 shares of company stock worth $2,944,621. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the stock. Binnacle Investments Inc purchased a new position in Hims & Hers Health in the third quarter valued at about $28,000. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter valued at about $30,000. Greenline Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $36,000. DV Equities LLC acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $46,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.